Selection of drugs for intraperitoneal chemotherapy for ovarian cancer

Intraperitoneal Therapy for Ovarian Cancer

Volumn , Issue , 2010, Pages 77-88

  Howell, Stephen B ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955814967     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-12130-2_7     Document Type: Chapter

References (34)

1. Trimble EL, Christian MC (2006) Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma. Gynecol Oncol 100:3-4
2. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1-11
3. Dedrick RL, Flessner MF (1997) Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 89:480-487
4. Howell SB, Zimm S, Markman M, Abramson IS, Cleary S, Lucas WE, Weiss RJ (1987) Longterm survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 5:1607-1612
5. Los G, Mutsaers PH, Lenglet WJ, Baldew GS, McVie JG (1990) Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 25:389-394
6. Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, Green M (1982) Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97:845-851
7. Kirmani S, Braly PS, McClay EF, Saltzstein SL, Plaxe SC, Kim S, Cates C, Howell SB (1994) A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol 54:338-344
8. Elferink F, Vander Vijgh WJF, Klein I, Ten Bokkel Huinink WW, Dubbleman R, McVie JG (1988) Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol 21:4157-4160
9. Howell SB, Pfeifle CE, Wung WE, Olshen RA (1983) Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 43:1426-1431
10. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr., Rubin S, Curtin J, Barakat R, Phillips M, Hurowitz L, Almadrones L, Hoskins W (1992) Phase I trial of intraperitoneal taxol: a gynecologic oncology group study. J Clin Oncol 10:1485-1491
11. Los G, Verdegaal EM, Mutsaers PH, McVie JG (1991) Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol 28:159-165
12. Jandial DD, Farshchi-Heydari S, Pu M, Messer K, Howell SB (2009) Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model. Gynecol Oncol 115:362-6. PMID: 19775736; PMCID: PMC2707998
13. Howell SB, Chu BB, Wung WE, Metha BM, Mendelsohn J (1981) Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. J Clin Invest 67:1161-1170
14. Esquis P, Consolo D, Magnin G, Pointaire P, Moretto P, Ynsa MD, Beltramo JL, Drogoul C, Simonet M, Benoit L, Rat P, Chauffert B (2006) High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg 244:106-112
15. Favoulet P, Magnin G, Guilland JC, Beltramo JL, Osmak L, Benoit L, Rat P, Douvier S, Duvillard C, Chauffert B (2001) Pre-clinical study of the epinephrine-cisplatin association for the treatment of intraperitoneal carcinomatosis. Eur J Surg Oncol 27:59-64
16. Molucon-Chabrot C, Isambert N, Benoit L, Zanetta S, Fraisse J, Guilland JC, Royer B, Monin-Baroille P, Flesch M, Fargeot P, Coudert B, Mayer F, Fumoleau P, Chauffert B (2006) Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis. Anticancer Drugs 17:1211-1217
17. Shah DK, Shin BS, Veith J, Toth K, Bernacki RJ, Balthasar JP (2009) Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy. J Pharmacol Exp Ther 329:580-591
18. Burger RA (2007) Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 25:2902-2908
19. King ME, Pfeifle CE, Howell SB (1984) Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma. J Clin Oncol 2:662-669
20. Kirmani S, Zimm S, Cleary SM, Mowry J, Howell SB (1990) Extremely prolonged continuous intraperitoneal infusion of cytosine arabinoside. Cancer Chemother Pharmacol 25:454-458
21. Muggia FM, Jeffers S, Muderspach L, Roman L, Rosales R, Groshen S, Safra T, Morrow CP (1997) Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/or carboplatin). Gynecol Oncol 66:290-294
22. Morgan RJ Jr., Synold TW, Xi B, Lim D, Shibata S, Margolin K, Schwarz RE, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Tetef M, Lin P, Paz B, Koczywas M, Wagman L, Chu D, Frankel P, Stalter S, Doroshow JH (2007) Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin Cancer Res 13:1232-1237
23. Sabbatini P, Aghajanian C, Leitao M, Venkatraman E, Anderson S, Dupont J, Dizon D, O'Flaherty C, Bloss J, Chi D, Spriggs D (2004) Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II trial. Clin Cancer Res 10:2962-2967
24. Armstrong DK, Fleming GF, Markman M, Bailey HH (2006) A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 103:391-396
25. Tsai M, Lu Z, Wang J, Yeh TK, Wientjes MG, Au JL (2007) Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel. Pharm Res 24:1691-1701
26. Vassileva V, Grant J, De Souza R, Allen C, Piquette-Miller M (2007) Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model. Cancer Chemother Pharmacol 60:907-914
27. Xu P, Van Kirk EA, Murdoch WJ, Zhan Y, Isaak DD, Radosz M, Shen Y (2006) Anticancer efficacies of cisplatin-releasing pH-responsive nanoparticles. Biomacromolecules 7:829-835
28. Carlson CB, Mowery P, Owen RM, Dykhuizen EC, Kiessling LL (2007) Selective tumor cell targeting using low-affinity, multivalent interactions. ACS Chem Biol 2:119-127
29. Dijkgraaf I, Kruijtzer JA, Frielink C, Corstens FH, Oyen WJ, Liskamp RM, Boerman OC (2007) Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. Int J Cancer 120:605-610
30. Holzer AK, Katano K, Klomp LW, Howell SB (2004) Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res 10:6744-6749
31. Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R, Howell SB (2004) The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol 66:817-823
32. Larson CA, Blair BG, Safaei R, Howell SB (2009) The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol 75:324-330
33. Holzer AK, Howell SB (2006) The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res 66:10944-10952
34. Jandial DD, Farshchi-Heydari S, Larson CA, Elliot GI, Wrasidlo WJ, Howell SB (2009) Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res 15:553-560